Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice
Pharmaceutics · 17.11.2026 · 18 (11) · 1484
DOI: 10.3390/pharmaceutics18111484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 17.11.2026. Verfasst von Mona M. Mostafa und 7 weiteren Autor:innen. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Background/Objectives: Breast cancer remains a major global health challenge, with the PI3K/AKT/mTOR signaling axis playing a key role in tumor progression. Drug repurposing offers an efficient approach to cancer therapeutics. Niflumic acid (NIF), a selective cyclooxygenase-2 (COX-2) inhibitor, has demonstrated antiproliferative and pro-apoptotic effects against breast cancer cells; however, its therapeutic potential is limited by its poor solubility. This study aimed to develop, optimize, and evaluate NIF-loaded aspasomes (NIF-ASPs) against solid Ehrlich carcinoma (SEC).
Methods
NIF-ASPs were optimized via a 21.41 full factorial design. The optimum (A2) formulation was evaluated for entrapment efficiency (EE%), vesicle size (VS), polydispersity index (PDI), zeta potential (ZP), and ex vivo permeation, using the skin as a model lipoidal barrier. Following intraperitoneal administration, the antitumor efficacy and associated changes in PI3K/AKT/mTOR signaling components were evaluated in SEC-bearing mice through RT-qPCR gene expression, biochemical assays, immunohistochemistry, and histopathology.
Results
The optimal A2 formula exhibited an EE% of 94.83 ± 0.16%, VS of 205.55 ± 2.05 nm, PDI of 0.49 ± 0.00, ZP of −23.65 ± 0.35 mV, and about a 2.59-fold increase in skin permeation flux versus free NIF suspension. In vivo, A2 was associated with a tumor inhibition rate of 63% (NIF suspension, 51.56%). Molecular and biochemical investigations demonstrated that A2 treatment was accompanied by significant alterations in PI3K/AKT/mTOR-associated molecular markers, characterized by decreased PI3K and p-AKT levels, together with downregulation of AKT and mTOR expression. Additionally, A2 treatment resulted in significant reductions in BCL-2, p-BAD, COX-2, and MDA levels, accompanied by restoration of total antioxidant capacity and a marked increase in cleaved caspase-3 immunoreactivity.
Conclusions
NIF-ASPs serve as an efficient delivery platform that significantly enhances the NIF ex vivo skin permeation and are associated with reduced tumor growth accompanied by alterations in the PI3K/AKT/mTOR pathway-related molecular markers, COX-2-related inflammation, and oxidative stress.
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Mostafa, M. M., El-Halim, S. M. A., William, M. M., Eltaweel, M. M., Amin, M. M., Omer, A. B., Selim, H. M. R. M., & Mosallam, S. (2026). Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice. Pharmaceutics, 18(11), 1484. https://doi.org/10.3390/pharmaceutics18111484
Vancouver
Mostafa MM, El-Halim SMA, William MM, Eltaweel MM, Amin MM, Omer AB, et al. Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice. Pharmaceutics. 2026;18(11):1484. doi:10.3390/pharmaceutics18111484
BibTeX
@article{Mostafa2026,
author = {Mostafa, Mona M. and El-Halim, Shady M. Abd and William, Mira Magdy and Eltaweel, Mai M. and Amin, Maha M. and Omer, Asma B. and Selim, Heba Mohammed Refat M. and Mosallam, Shaimaa},
title = {Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1484},
doi = {10.3390/pharmaceutics18111484}
}
EUVIMED